Top

Published in:

01-09-2009 | Clinical Trial

Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO)

Authors: J. Y. Petit, U. Veronesi, R. Orecchia, P. Rey, S. Martella, F. Didier, G. Viale, P. Veronesi, A. Luini, V. Galimberti, R. Bedolis, M. Rietjens, C. Garusi, F. De Lorenzi, R. Bosco, A. Manconi, G. B. Ivaldi, O. Youssef

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

In order to reduce mutilation, nipple-areola complex (NAC) conservation can be proposed for the treatment of breast cancer when mastectomy is indicated. To reduce the risk of retro areolar recurrence, a novel radiosurgical treatment combining subcutaneous mastectomy with intraoperative radiotherapy (ELIOT) is proposed. One thousand and one nipple sparing mastectomies (NSM) were performed from March 2002 to November 2007 at the European institute of oncology (EIO), for invasive carcinoma in 82% of the patients and in situ carcinoma in 18%. Clinical complications, aesthetic results, oncological and psychological results were recorded. A comparison was performed between the 800 patients who received ELIOT and the 201 who underwent delayed one-shot radiotherapy on the days following the operation. The median follow up time was 20 months (range 1–69) for a follow up performed in 83% of the patients. The NAC necrosed totally in 35 cases (3.5%) and partially in 55 (5.5%) and was removed in 50 (5%). Twenty infections (2%) were observed and 43 (4.3%) prostheses removed. The median rate of the patients for global cosmetic result on a scale ranging from 0 (worst) to 10 (excellent) was 8. Evaluation by the surgeon in charge of the follow-up gave a similar result. Only 15% of the patients reported a partial sensitivity of the NAC. Of the fourteen (1.4%) local recurrences, ten occurred close to the tumour site, all far from the NAC corresponding to the field of radiation. No recurrences were observed in the NAC. In a group of patients characterized by a very close free margin under the areola, no local recurrence was observed. Overall, 36 cases of metastases and 4 deaths were observed. No significant outcome difference was observed between the 800 patients receiving intraoperative radiotherapy (ELIOT) and the 201 patients receiving delayed irradiation.

Veronesi U, Volterrani F, Luini A et al (1990) Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 26(6):671–673PubMedCrossRef

Carlson GW, Losken A, Moore B et al (2001) Results of immediate breast reconstruction after skin-sparing mastectomy. Ann Plast Surg 46(3):222–228PubMedCrossRef

Carlson GW, Bostwick JRD, Styblo TM et al (1997) Skin-sparing mastectomy oncologic and reconstructive considerations. Ann Surg 225(5):570–575PubMedCrossRef

Peyser PM, Abel JA, Straker VF et al (2000) Ultra conservative skin-sparing “keyhole” mastectomy and immediate breast and areola reconstruction. Ann R Coll Surg Engl 82(4):227–235PubMed

Ho CM, Mak CK, Lau Y et al (2003) Skin involvement in invasive breast carcinoma: safety of skin sparing-mastectomy. Ann Surg Oncol 10(2):102–107PubMedCrossRef

Carlson GW, Styblo TM, Lyles RH et al (2003) Local recurrence after skin-sparing mastectomy: tumor biology or surgical conservatism? Ann Surg Oncol 10(2):108–112PubMedCrossRef

Simmons RM, Fish SK, Gayle L et al (1999) Local and distant recurrence rates in skin-sparing mastectomy compared with non-skin-sparing mastectomies. Ann Surg Oncol 6(7):676–678PubMedCrossRef

Slavin SA, Schnitt SJ, Duda RB et al (1998) Skin-sparing mastectomy and immediate reconstruction: oncologic risks and aesthetic results in patients with early stage breast cancer. Plast Reconstr Surg 102(1):49–62PubMedCrossRef

Kroll SS, Khoo A, Singletary SE et al (1999) Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg 104(2):421–425PubMedCrossRef

10.

Medina-Franco H, Vasconez LO, Fix RJ et al (2002) Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 235(6):814–819PubMedCrossRef

11.

Beer GM, Varga Z, Budi S et al (2002) Incidence of the superficial fascia and its relevance in skin-sparing mastectomy. Cancer 94(6):1619–1625PubMedCrossRef

12.

Wellisch DK, Schain WS, Noone RB, Little JWIII (1987) The psychological contribution of nipple addition in breast reconstruction. Plast Reconstr Surg 80(5):699–704PubMedCrossRef

13.

Cense HA, Rutgers EJ, Lopes-Cardozo M, Van Lanschot JJ (2001) Nipple sparing mastectomy in breast cancer: a viable option? Eur J Surg Oncol 6:521–526CrossRef

14.

Lambert PA, Kolm P, Perry RR (2000) Parameters that predict nipple involvement in breast cancer. J Am Coll Surg 191(4):354–359PubMedCrossRef

15.

Gajdos C, Tartter PI, Bleiweiss IJ (2000) Subareolar breast cancers. Am J Surg 180(3):167–170PubMedCrossRef

16.

Vyas JJ, Chinoy RF, Vaidya JS (1998) Prediction of nipple and areola involvement in breast cancer. Eur J Surg Oncol 24(1):15PubMedCrossRef

17.

Laronga C, Kemp B, Johnston D, Robb GL, Singletary SE (1999) The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin sparing mastectomy. Ann Surg Oncol 6:609–613PubMedCrossRef

18.

Gerber B, Krause A, Reimer T et al (2003) Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg 238(1):120–127PubMedCrossRef

19.

Merrick HW, Battle JA, Padgett BJ, Dobelbower RR (1997) ELIOT for early breast cancer: a report on long-term results. Front Radiat Ther Oncol 31:126–130PubMedCrossRef

20.

Petit JY, Veronesi U, Orecchia R et al (2003) The nipple-sparing mastectomy: early results of a feasibility study of a new application of perioperative radiotherapy (ELIOT) in the treatment of breast cancer when mastectomy is indicated. Tumori 89:288–291PubMed

21.

DuBois J-B, Hay M, Gely S, Saint-Aubert B, Rouanet P, Pujol H (1997) ELIOT in breast carcinomas. Front Radiat Ther Oncol 31:131–137PubMedCrossRef

22.

Battle JA, DuBois J-B, Merrick HW, Dobelbower RR (1999) ELIOT for breast cancer. In: Gunderson LL et al (eds) Current clinical oncology: intraoperative irradiation: techniques and results. Humana Press. Inc, New York, pp 521–526

23.

Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Veronesi P et al (2001) Focalised intraoperative irradiation after conservative surgery for early stage breast cancer. The breast 10(Suppl 3):84–89

24.

Veronesi U, Orecchia R, Luini A et al (2001) A preliminary report of intraoperative radiotherapy (ELIOT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37:2178–2183PubMedCrossRef

25.

Benediktsson KP, Perbeck L, Geigant E, Solders G (1997) Touch sensibility in the breast after subcutaneous mastectomy and immediate reconstruction with a prosthesis. Br J Plast Surg 50(6):443–449PubMedCrossRef

26.

Simmons RM, Brennan M, Christos P et al (2002) Analysis of nipple/areolar involvement with mastectomy: can areola be preserved? Ann Surg Oncol 9(2):165–168PubMedCrossRef

27.

Chagpar AB (2004) Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative and postoperative considerations. Am Surg 70(5):425–432PubMed

28.

Crowe JP Jr, Kim JA, Yetman R, Bambury J, Patrick RJ, Baynes D (2004) Nipple-sparing mastectomy: technique and results of 54 procedures. Arch Surg 139(2):148–150PubMedCrossRef

29.

Simmons RM, Hollenbeck ST, Latrenta GS (2003) Areola-sparing mastectomy with immediate breast reconstruction. Ann Plast Surg 51(6):547–551PubMedCrossRef

Title: Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO)
Authors: J. Y. Petit
U. Veronesi
R. Orecchia
P. Rey
S. Martella
F. Didier
G. Viale
P. Veronesi
A. Luini
V. Galimberti
R. Bedolis
M. Rietjens
C. Garusi
F. De Lorenzi
R. Bosco
A. Manconi
G. B. Ivaldi
O. Youssef
Publication date: 01-09-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0304-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania

Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma

Kwan’s arm problem scale: psychometric examination in a sample of stage II breast cancer survivors

Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

Silencing of estrogen receptor α (ERα) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer